Torrent Pharmaceuticals has announced the successful conclusion of a USFDA inspection at its Dahej manufacturing facility. The inspection, which took place from January 19-26, 2026, ended with zero observations. This outcome indicates adherence to high-quality manufacturing standards and is a positive development for the company’s operations. The facility is a key part of Torrent’s manufacturing network.
USFDA Inspection Update
Torrent Pharmaceuticals has announced the completion of a USFDA (United States Food and Drug Administration) inspection at its Dahej manufacturing facility. The inspection took place from January 19, 2026, to January 23, 2026.
Zero Observation Outcome
The announcement highlights a significant outcome: the USFDA inspection concluded with zero observations. This result signifies that the Dahej manufacturing facility meets the stringent quality and compliance standards set by the USFDA. It is an indication of the facility’s robust operational controls and adherence to good manufacturing practices.
Source: BSE
